kanamycin B

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: kanamycin B
• 英文别名: Kanamycin B,(S)；(2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1S,2R,3R,4S,6R)-4,6-diamino-3-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4-diol
• 化学式: C₁₈H₃₇N₅O₁₀
• 分子量: 483.519
• InChiKey: SKKLOUVUUNMCJE-BNWSHAKYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -7.2
• 重原子数：
  33
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  288
• 氢给体数：
  11
• 氢受体数：
  15

反应信息

• 作为反应物：
  描述：

  苯甲醛二甲缩醛 、 kanamycin B 在 对甲苯磺酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成
  参考文献：
  名称：

  阿贝卡星中间体的制备方法

  摘要：

  本发明公开了一种阿贝卡星中间体的制备方法，先将对甲基苯磺酸、卡那霉素B和PhCH(OMe)2混合反应对卡那霉素B的4″，5″位的羟基成环保护，然后用R基团(R＝BnSO2)取代1、3、2′，5′，3″位‑NH2和3′、4′、2″位‑OH的氢原子，接着去除3′、4′位的‑OR基团并且4″，5″位开环，最后脱除R(R＝BnSO2)基团保护得到阿贝卡星中间体。本发明的阿贝卡星中间体的制备方法路线简单，简化了合成工艺；并且最终产率高，产率达到53.4％，得到的中间体纯度高，纯度为98％。第一步使用的保护试剂二甲氧基苯基甲烷便宜易得。

  公开号：

  CN106946957B

文献信息

• 1H-NMR analysis of copper-aminoglycoside complexes in solution and its implication for regioselective modification of multifunctional aminoglycoside antibiotics
  作者：Ioannis Grapsas、Irina Massova、Shahriar Mobashery

  DOI：10.1016/s0040-4020(98)00407-4

  日期：1998.7

  A method for analysis of complexes of the cupric ion with aminoglycoside antibiotics based on the measurement of the paramagnetic contribution of the cupric ion to T-1 relaxation time on H-1-NMR spectra of the antibiotics is described. The information from the NMR experiments was supplemented by molecular modeling studies and proved valuable in predicting the reactivities of these complexes toward reagents for modification of amines, which were used in regioselective, and often regiospecific, derivatization of these important antibiotics. (C) 1998 Elsevier Science Ltd. All rights reserved.
• ENGINEERED SUBSTRATES FOR HIGH-THROUGHPUT GENERATION OF 3D MODELS OF TUMOR DORMANCY, RELAPSE AND MICROMETASTASES FOR PHENOTYPE SPECIFIC DRUG DISCOVERY AND DEVELOPMENT
  申请人：Rege Kaushal

  公开号：US20170115275A1

  公开（公告）日：2017-04-27

  Methods to form a novel aminoglycoside based hydrogel for high-throughput generation of 3D dormant, relapsed and micrometastatic tumor microenvironments are disclosed. In addition, methods of screening agents against tumor cells grown in the 3D environments disclosed herein that include, for example, screening of lead drugs and therapies for an effect on dormant, relapsed and/or micrometastatic tumor cells.